May 8, 2017 07:31 AM EDT

Building an orphan pipeline, Horizon Pharma bags PhIII-ready rare disease drug in $145M buyout

John Carroll

Editor & Founder

Eight months after a little-known subsidiary group named River Vision Development Corp. won a breakthrough therapy designation for its lead drug for a rare …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Building an orphan pipeline, Horizon Pharma bags PhIII-ready rare disease drug in $145M buyout

John Carroll

Editor & Founder

Sign up to read this article for free.

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Novartis to cut 139 jobs in NJ as part of commercial refocus

Build­ing an or­phan pipeline, Hori­zon Phar­ma bags PhI­II-ready rare dis­ease drug in $145M buy­out

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Building an orphan pipeline, Horizon Pharma bags PhIII-ready rare disease drug in $145M buyout

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Novartis to cut 139 jobs in NJ as part of commercial refocus